T
Theradiag Group/Prestizia
Developing, manufacturing, and marketing innovative in-vitro diagnostics
About Theradiag Group/Prestizia
Theradiag, established in 1986 by two former executives of Abbott France, is a company specializing in in-vitro diagnostics (IVD) and theranostics. Initially focused on distributing IVD tests for autoimmune diseases, the company has since expanded its operations significantly. A major turning point was its initial public offering on the NYSE Alternext in December 2012, at which time it changed its name from BMD to Theradiag. In December 2023, Theradiag completed a merger-absorption by Biosynex.
The company's business is structured around two main activities: In-Vitro Diagnostics and Theranostics. The IVD segment covers both in-house manufactured products and distributed products in fields such as autoimmunity, allergies, and infectious diseases. The Theranostics division, a key growth driver, focuses on providing personalized medicine solutions for monitoring biotherapies used in treating autoimmune diseases and cancer. This is centered around its flagship LISA TRACKER® range, a comprehensive set of tests for monitoring monoclonal antibodies. Revenue is generated through the sale of these diagnostic kits and reagents, as well as through licensing agreements and the sale of raw materials to partners. For the fiscal year 2022, Theradiag reported revenue of €12.2 million.
Theradiag's product portfolio is designed to aid clinicians in customizing treatments, evaluating their efficacy, and preventing drug resistance. Key products include the CE-marked TRACKER® range, which has expanded into oncology for monitoring treatments like Rituximab and Bevacizumab. The company also develops and markets the i-Tracker® range of tests adapted for its i-Track10 automated system, which has been a significant contributor to sales growth. Furthermore, Theradiag has developed ez-TRACKER®, a point-of-care testing machine for on-site diagnostics. The firm's expertise in diagnostics for autoimmune diseases is supported by its multiplex test range using Luminex® technology. In 2012, Theradiag acquired Prestizia to develop new diagnostic markers using a microRNA platform. However, this subsidiary was closed in 2017 after research programs were deemed not robust enough for commercialization.
Source: Dealroom company dataNews
Open roles
Theradiag Group/Prestizia in the Croissy-Beaubourg ecosystem
The Theradiag Group/Prestizia office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Ventech
Auriga Partners- ICInnovation Capital
Sofinnova Investments
Siparex
Eurazeo
Truffle Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Theradiag Group/Prestizia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Theradiag Group/Prestizia on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


